Anti-BCMA CAR Antibody Conjugates for Precise T-Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for measuring and tracking anti-BCMA CAR expression and activity in CAR T cells are inadequate, making it difficult to precisely correlate ex vivo and in vivo expression and persistence, which complicates the assessment of CAR T cell activity.
Innovation Solution
Development of antibodies and antigen binding fragments that specifically bind to anti-BCMA CAR, conjugated with detectable labels, allowing for precise detection and measurement of CAR expression and persistence using techniques such as immunohistochemistry, ELISA, and flow cytometry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If quantitative PCR using CAR-specific primers is used to assess CAR T cells, then CAR expression can be measured, but multi-parameter analysis capability is lost
Solution Approach 1:
The patent divides the detection capability into separate functional modules: CAR-specific detection through antibody binding and flow cytometry, and simultaneous detection of other cell surface markers through multi-color flow cytometry panels. This segmentation allows each detection modality to optimize for its specific function while maintaining overall multi-parameter analysis capability.
Solution Approach 2:
The patent employs flow cytometry as a universal detection platform that can simultaneously perform CAR expression measurement and multi-parameter phenotypic analysis. By using a single instrument and sample preparation approach for multiple detection purposes, the system achieves both precise CAR quantification and versatile cell characterization without requiring separate specialized assays.
2Measurement precision
If existing detection methods are used for CAR T cells, then some measurement capability is provided, but precise correlation of ex vivo and in vivo expression and persistence is compromised
Solution Approach 1:
The patent detects CAR expression on the cell surface using antibody binding and flow cytometry, measuring the actual functional CAR protein present on living cells rather than genetic templates. This parameter change from genetic detection to protein expression detection provides a more accurate reflection of functional CAR T cells that correlates better between ex vivo and in vivo conditions.
3Ease of operation
If CAR T cell activity assessment is performed with existing methods, then basic detection is possible, but accurate assessment of CAR T cell activity and persistence is complicated
Solution Approach 1:
The patent uses surface-bound antibodies as intermediaries that specifically recognize and bind to CAR proteins on T cell surfaces. These antibody intermediaries enable precise detection of CAR expression levels and facilitate subsequent analysis of CAR T cell activity and persistence through flow cytometry, providing an accurate and operationally simple assessment method.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate detection and quantification of anti-BCMA CAR expression on T cells, facilitating improved assessment of CAR T cell activity and persistence.
Implementation Method 1
antibodies and antigen binding fragments that bind an anti-BCMA CAR
Data Source
AI summary
The invention provides improved methods for detecting anti-BCMA CAR expression on T cells. The invention generally provides antibodies and antigen binding fragments thereof, conjugates thereof, and methods of using the same to detect, determine, or measure CAR T cells and/or CAR expression on one or more T cells.